A novel multi-omics and network pharmacology study has elucidated interactions between gut microbiota metabolites and matrix metalloproteinase-3 (MMP-3) in breast cancer progression. Researchers Yuan, Xing, and Liu demonstrated how microbial metabolites can regulate MMP-3 activity, influencing tumor microenvironment dynamics and potentially modulating cancer metastasis. These insights suggest the gut microbiome’s metabolic contributions are significant in breast cancer pathophysiology, offering new opportunities for therapeutic intervention targeting host-microbe interactions.